CAS: 1249-84-9; (3S,8R,9S,10R,13S,14S,17S)-17-[3-(Dimethylamino)Propyl-Methylamino]-10,13-Dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-Dodecahydro-1H-Cyclopenta[a]Phenanthren-3-Ol,Dihydrochloride

专利信息

专利号:WO-2022061431-A1
优先权日:2020-09-23
标题 :Delta 24-sterol methyltransferase enzyme inhibitor metalloazasterol compound, pharmaceutical composition and use of the compound
发明人：GUILLERMO VISBAL SILVA GONZALO; COROMOTO NAVARRO ACOSTA MARIBEL; MANOEL DA SILVA JUSTO RODRIGO; COLA FERNANDES RODRIGUES JULIANY; TEIXEIRA DE MACEDO SILVA SARA; DE SOUZA WANDERLEY; DOS SANTOS DA SILVA GABRIELLE
权利人:INSTITUTO NAC DE METROLOGIA QUALIDADE E TECNOLOGIA INMETRO; UNIV FEDERAL DE JUIZ DE FORA UFJF; UNIV FEDERAL DO RIO DE JANEIRO UFRJ
摘要:The present invention relates to a novel compound, dichlorobis(22-hydrazone-imidazoline-2-yl-chol-5-en-3-beta-ol)zinc(II), which consists of a metalloazasterol that results from complexing zinc with two 22-hydrazone-imidazoline-2-yl-chol-5-en-3-beta-ol (H3) molecules and selectively inhibits the enzyme delta 24-sterol methyltransferase (24-EMT), which is essential for the synthesis of ergosterol and other 24-alkylated sterols found in the membrane of parasites and fungi, therefore being particularly useful for treating parasitic diseases, such as leishmaniasis and Chagas disease, and fungal diseases. Other aspects of the present invention consist of a pharmaceutical composition comprising the novel compound and also use thereof.

专利号:CN-101838675-A
优先权日:2010-05-13
标题:A method of using supercritical CO2 as a solubilizing agent to catalyze the synthesis of phytosterol esters

专利号:US-5219879-A
优先权日:1990-03-05
标 题 :Heterocyclic steroid compounds
发明人：KO SOO S; TRZASKOS JAMES M
权利人:DU PONT MERCK PHARMA
摘要:The present invention relates to novel substituted 15-oxa-, 15-thia-, and 15-aza- dihydrolanosterols, to pharmaceutical compositions containing such compounds, and to methods of using these compounds to suppress the activity of 3-hydroxy-3- methylglutaryl coenzyme A reductase (HMGR), an enzyme which is important in cholesterol biosynthesis. The overall effect of these heterocyclic lanosterol analogs is to decrease cholesterol formation, thereby resulting in lower serum cholesterol levels in mammals, and impaired ergosterol synthesis in fungi.